| Business Summary | | Helix
BioMedix,
Inc.
is
actively
engaged
in
the
research
and
development
of
lytic
peptides
(small
bioactive
proteins)
and
their
commercial
applications.
Since
March
1989,
the
Company
has
been
involved
in
the
business
of
conducting
research
into
the
nature
of
and
commercial
uses
for
lytic
peptides
in
house;
through
a
contract
arrangement
with
Louisiana
State
University
(LSU);
through
a
collaboration
with
a
private
sector
research
company,
Therapeutic
Peptides
Inc.
(TPI);
and
by
outsourcing
certain
laboratory
testing
to
contract
research
organizations. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Helix
Biomedix,
Inc.
is
engaged
in
the
research
and
development
of
lytic
peptides
(small
bioactive
proteins)
and
their
commercial
applications.
The
Company
conducts
research
in
house,
as
well
as
through
outside
arrangements
and
collaborations.
For
the
six
months
ended
6/30/01,
the
company
reported
no
revenues.
Net
loss
rose
6%
to
$1.2
million.
Results
reflect
increased
professional
and
consulting
expenses
and
lower
interest
income. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Keith Lanneau, 75 Chairman,
VP- Technology | $90K | R. Stephen Beatty, 51 Pres,
CEO, Director | 78K | Thomas Frazer, 53 CFO,
Treasurer, VP, Director | -- | Elizabeth Scheer, 50 VP-
Investor Relations & Corp. Communications and Sec. | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|